An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) announced that CEO N. Scott Fine will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company is focused on developing innovative treatments for diseases, particularly Niemann-Pick Disease Type C. A video webcast of the presentation will be available on-demand starting September 13, 2021. Cyclo Therapeutics is advancing its product Trappsol® Cyclo™, currently in multiple clinical trials, and plans to initiate early-phase Alzheimer’s Disease trials based on promising data.
Positive
None.
Negative
None.
GAINESVILLE, Fla.--(BUSINESS WIRE)--
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be available for viewing on-demand beginning on Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (www.cyclotherapeutics.com). The webcast replay will be archived for 90 days following the event.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.govNCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.
Investor Contact:
JTC Team, LLC Jenene Thomas (833) 475-8247
CYTH@jtcir.com
Source: Cyclo Therapeutics, Inc.
FAQ
When will Cyclo Therapeutics present at the H.C. Wainwright 23rd Annual Global Investment Conference?
Cyclo Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.
Who is presenting for Cyclo Therapeutics at the conference?
N. Scott Fine, the CEO of Cyclo Therapeutics, will present at the conference.
What is the focus of Cyclo Therapeutics' research?
Cyclo Therapeutics focuses on developing treatments for diseases, especially Niemann-Pick Disease Type C.
Will there be a webcast of the presentation?
Yes, a video webcast will be available for on-demand viewing starting September 13, 2021.
What is Trappsol® Cyclo™ and its relevance?
Trappsol® Cyclo™ is Cyclo Therapeutics' product in clinical trials for Niemann-Pick Disease Type C and is planned for use in Alzheimer’s Disease trials.
